The dilutive offering at a 2.8% discount to the current price (assuming $3.60 close) adds overhang. Monitor for further dilution if the shelf is tapped again. The company's cash runway extends but at the cost of shareholder value.
Price Chart
Executive Summary
NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes to support the company's clinical-stage pipeline for CNS disorders.
Key Financial Metrics
Key Facts
- Closed underwritten public offering of common stock at $3.50 per share
- Gross proceeds of approximately $22.3 million
- Proceeds to be used for working capital and general corporate purposes
- BTIG and Lucid Capital Markets acted as bookrunners
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
Dilution of approximately 6.37 million shares at $3.50 per share, representing about 15% of pre-offering shares outstanding (based on $147M market cap / $3.50 = 42M shares pre-offering). Gross proceeds of $22.3 million.
Risk Factors
- Further dilution from remaining shelf capacity
- Clinical-stage pipeline with no approved products; regulatory and commercial risks
- Potential for additional capital raises given operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307137 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access